Kyowa Hakko Kirin
 |
|
 |
|
| Public KK | |
| Traded as | : : KY4 Nikkei 225 Component |
| Industry | |
| Founded | July 1, 1949 |
| Headquarters | Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan |
|
Key people
|
Nobuo Hanai, (CEO and President) |
| Products | |
| Revenue |
 (¥ 340.61 billion JPY) (FY 2013) |
|
(¥ 30.07 billion JPY) (FY 2013) |
|
|
Number of employees
|
7,152 (consolidated) (as of December 31, 2013) |
| Parent | Kirin Holdings Company, Limited |
| Subsidiaries | 47 (33 in Japan and 14 overseas countries) |
| Website | Official website |
|
Footnotes / references |
|
Kyowa Hakko Kirin Co., Ltd. (協和発酵キリン株式会社 Kyōwa Hakkō Kirin Kabushiki Kaisha?) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.
On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.
On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million
...
Wikipedia